ERBB2 and breast carcinoma: In patients with breast cancer (n = 75,553), the HRs for ATE were 0.81 (95% CI: 0.64–1.04) with HER2-targeted therapy (n = 9246) and 0.73 (95% CI: 0.30–1.76) with CDK4/6-inhibitors (n = 1800).